Injection Site Reaction
10
0
0
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
50%
5 trials in Phase 3/4
38%
3 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (10)
Prospective Study to Assess Tissue Responses After Injection With Biostimulatory Products
Safety of Pediatric COVID-19 Vaccination
Simultaneous RZV and aIIV4 Vaccination
Naldebain and Video-assisted Thoracoscopic Surgery
Simultaneous mRNA COVID-19 and IIV4 Vaccination Study
Sorrel 25R Injector - Sorrel Clinical Study Protocol
Evaluation of Deltoid Exercises on Injection Site Pain After (BNT162b2) COVID - 19 Vaccination
FLUAD® vs. Fluzone® High-Dose Study
A Study Comparing the Local Tolerability of Two Subcutaneous Heparins in Healthy Volunteers.
Effectiveness of Mechano-Analgesia and Cold Application on Ecchymosis, Pain and Satisfaction at Subcutaneous Heparin Injection